| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$136 |
Actinogen HY2025 financial report and Appendix 4D
|
26 Feb 2026 10:26AM |
$0.041 |
$0.037 |
fallen by
10.98%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited reported a net loss after tax of $11,346,952 for the half-year ended 31 December 2025, compared to a loss of $8,168,979 for the previous year.
- The company's total revenue and other income increased to $2,107,063 from $244,406 the previous year.
- Research and development costs significantly increased to $8,902,759, reflecting ongoing clinical trials and development activities.
- The company's cash and cash equivalents decreased from $16,504,230 as of 30 June 2025 to $6,531,460 as of 31 December 2025.
- The total equity of Actinogen Medical Limited decreased from $18,335,903 as of 30 June 2025 to $8,368,615 as of 31 December 2025.
- The R&D tax rebate for FY25 amounted to $5,489,600 and was fully received by the company.
- The company issued new shares during the half-year, increasing contributed equity to $116,196,238.
- Actinogen launched an InvestorHub platform in September 2025 to enhance communication with investors.
- The report included a detailed statement of financial position and changes in equity, emphasizing the impact of R&D expenses and share-based payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wide Open Agriculture Ltd (WOA) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 10:24AM |
$0.016 |
$0.009 |
fallen by
43.75%
|
|
WOA - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for half-year ended 31 December 2025 was $2,052,935.
- Revenue increased by 41% to $381,225 compared to the previous year.
- Focus on cost reduction and capital management to extend cash runway.
- $1.5 million in cash held as of 31 December 2025.
- Strong demand for lupin protein isolate and development of lupin oil and fiber.
- Exploration of contract manufacturing to meet demand and reduce costs.
- Directors believe the company will continue as a going concern.
- Potential R&D tax refund, equity raising, and asset disposals identified as financial strategies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coast Entertainment Holdings Limited (CEH) ORDINARY FULLY PAID |
Consumer Discretionary |
$175 |
Change of Director's Interest Notice - David Haslingden
|
26 Feb 2026 10:22AM |
$0.540 |
$0.450 |
fallen by
16.67%
|
|
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$14 |
Media Release - December 2025 half-years results
|
26 Feb 2026 10:21AM |
$0.078 |
$0.056 |
fallen by
28.21%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for HY26 was $3.1 million, a 9% increase from the prior year.
- AUM grew by 7% to AUD 5.02 billion as of 31 December 2025.
- After-tax loss of $369,179 due to strategic investments.
- Focus on profitability and scalable growth.
- Strong financial position with $7.2 million in cash.
- Continued investment in team and operational capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$14 |
Half Yearly Report and Accounts
|
26 Feb 2026 10:20AM |
$0.078 |
$0.056 |
fallen by
28.21%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- K2 Asset Management Holdings Ltd reported a comprehensive loss of $369,179 for the half-year ended 31 December 2025.
- Total revenue for the half-year increased by 8.7% to $3,115,797 compared to the previous corresponding period.
- The company paid a final dividend of 0.50 cents per share, fully franked, on 30 September 2025.
- Employee benefits and marketing expenses were significant cost items impacting financial performance.
- No new equity issuances occurred during the half-year period.
- The company operates solely within Australia's financial services sector.
- Cash and cash equivalents decreased, affecting overall liquidity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Bond Exchange Holdings Limited (ABE) ORDINARY FULLY PAID |
Financials |
$2 |
Application for quotation of securities - ABE
|
26 Feb 2026 10:18AM |
$0.030 |
$0.013 |
fallen by
56.67%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,492 |
Final Director's Interest Notice - Graeme Barclay
|
26 Feb 2026 10:17AM |
$5.130 |
$4.730 |
fallen by
7.80%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,492 |
Change of Director's Interest Notice - Phillip Britt
|
26 Feb 2026 10:15AM |
$5.130 |
$4.730 |
fallen by
7.80%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,492 |
Change of Director's Interest Notice - Sarah Adam-Gedge
|
26 Feb 2026 10:15AM |
$5.130 |
$4.730 |
fallen by
7.80%
|
|
| Austin Engineering Limited (ANG) ORDINARY FULLY PAID |
Industrials |
$87 |
Update - Dividend/Distribution - ANG
|
26 Feb 2026 10:15AM |
$0.183 |
$0.140 |
fallen by
23.29%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,492 |
Change of Director's Interest Notice - Sue Klose
|
26 Feb 2026 10:15AM |
$5.130 |
$4.730 |
fallen by
7.80%
|
|
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$215 |
BXN H1 FY2026 Results Presentation
|
26 Feb 2026 10:14AM |
$0.058 |
$0.940 |
risen by
1,520.69%
|
|
BXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue of $31.3 million for H1 FY2026, up 149% from PCP.
- Adjusted EBITDA of $8.3 million, an increase of 137% year-on-year.
- Upgraded FY2026 EBITDA guidance to $16.5-19 million.
- Expansion into new markets including the UK, Germany, and LATAM.
- New contracts with Curaleaf, Remidose, and Adrex.
- Significant investment in inventory to support future demand.
- World's largest GMP-certified cannabis pastilles facility.
- Dual listing completed on the Frankfurt Stock Exchange.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,492 |
Change of Director's Interest Notice - Adrian Fitzpatrick
|
26 Feb 2026 10:14AM |
$5.130 |
$4.730 |
fallen by
7.80%
|
|
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$57 |
Botanix Webinar - 3 March - Registration Information
|
26 Feb 2026 10:13AM |
$0.057 |
$0.021 |
fallen by
63.16%
|
|
| RMA Global Limited (RMY) ORDINARY FULLY PAID |
Communication Services |
$18 |
Investor Update February 2026
|
26 Feb 2026 10:13AM |
$0.045 |
$0.027 |
fallen by
40%
|
|
RMY - Price-sensitive ASX Announcement
Full Release
Key Points
- RMA Global Limited focuses on the US real estate market with a strategy to increase penetration and market share.
- The company's new marketing approach emphasizes becoming a local authority and maintaining a consistent online presence.
- RMA Global highlights the importance of agent reviews and structured online presence for real estate success.
- The company offers tools and partnerships to real estate brokerages to enhance agent visibility and credibility.
- RMA Global targets a significant market opportunity valued at approximately AUD$341 million in the US.
- The presentation outlines a multi-year agreement with a network of 75,000 agents in the US and Canada.
- RMA Global's strategy includes automated systems for review collection and social media marketing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metro Mining Limited (MMI) ORDINARY FULLY PAID |
Materials |
$535 |
Webinar Invitation to Shareholders
|
26 Feb 2026 10:13AM |
$0.065 |
$1.740 |
risen by
2,576.92%
|
|
| SenSen Networks Limited (SNS) ORDINARY FULLY PAID |
Information Technology |
$20 |
Investor Presentation
|
26 Feb 2026 10:12AM |
$0.052 |
$0.024 |
fallen by
53.85%
|
|
| SenSen Networks Limited (SNS) ORDINARY FULLY PAID |
Information Technology |
$20 |
FY26 Half-Year Results
|
26 Feb 2026 10:12AM |
$0.052 |
$0.024 |
fallen by
53.85%
|
|
SNS - Price-sensitive ASX Announcement
Full Release
Key Points
- Record first-half revenue of $6.59 million with 20.2% growth.
- 115% increase in usage revenue.
- Annualized Recurring Revenue grew by 24.7% to $10.6 million.
- Cash receipts increased by 31% to $8.3 million.
- Gross margin improved to 85.2%.
- Positive EBITDA of $0.34 million.
- Expansion in North America with five new city clients.
- 33 new fuel retail sites in Australia.
- Rollout of SenPIC cameras in Victoria.
- Improved net loss after tax of $171,805.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SenSen Networks Limited (SNS) ORDINARY FULLY PAID |
Information Technology |
$20 |
Appendix 4D & Interim Financial Report
|
26 Feb 2026 10:11AM |
$0.052 |
$0.024 |
fallen by
53.85%
|
|
SNS - Price-sensitive ASX Announcement
Full Release
Key Points
- Record first half revenues of $6.59 million, a 20% increase from the prior year.
- Significant improvement in net loss after tax to $171,805 from $1.59 million.
- Gross margin improved to 85% from 77% in the previous comparative period.
- Strong sales momentum in North America with new city wins.
- 33 additional fuel retail site orders in Australia, including from Ampol.
- No dividends declared for the half-year.
- Issued shares under a long-term incentive plan.
- Managed financial liabilities including repayments and new borrowings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alvo Minerals Limited (ALV) ORDINARY FULLY PAID |
Materials |
$7 |
Touro Drilling Results Confirm Additional Copper Intercepts
|
26 Feb 2026 10:11AM |
$0.040 |
$0.026 |
fallen by
35%
|
|
ALV - Price-sensitive ASX Announcement
Full Release
Key Points
- Drill assays confirmed additional copper intercepts at Touro Prospect.
- Significant intercepts include 5.1m at 1.1% CuEq in PDT-120 and 3.6m at 0.9% CuEq in PDT-121.
- Exploration continues to assess deeper conductors and expand the resource.
- Geophysical and geochemical surveys are underway at Esperanza and Entre Rios.
- The drilling campaign is part of Alvo's broader strategy at the Palma VMS Project in Brazil.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$11,202 |
Form 4 as filed - Brian Tabolt
|
26 Feb 2026 10:09AM |
$174.540 |
$142.170 |
fallen by
18.55%
|
|
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$11,202 |
Form 4 as filed - David Fry
|
26 Feb 2026 10:09AM |
$174.540 |
$142.170 |
fallen by
18.55%
|
|
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$11,202 |
Form 4 as filed - David Thornton
|
26 Feb 2026 10:09AM |
$174.540 |
$142.170 |
fallen by
18.55%
|
|
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$11,202 |
Form 4 as filed - Francois Hardy
|
26 Feb 2026 10:09AM |
$174.540 |
$142.170 |
fallen by
18.55%
|
|
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$11,202 |
Form 4 as filed - Jen Cmil
|
26 Feb 2026 10:08AM |
$174.540 |
$142.170 |
fallen by
18.55%
|
|